Biogen kept at neutral by Merrill

Biogen Idec Inc. was maintained by Merrill Lynch analyst Eric Ende at a neutral rating. The company reported fourth-quarter 2005 earnings per share or $0.48, close to Merrill's estimate of $0.50 and consensus of $0.47. The analyst's focus will stay on the sBLA for Rituxan in rheumatoid arthritis and Tysabri for multiple sclerosis. The Food and Drug Administration lifted the clinical hold of Tysabri but remains concerned about the risk of PML. Shares of the Cambridge, Mass., pharmaceutical company were up $1.61, or 3.52%, at $47.33 on volume of 6,459,261 shares versus the three-month running average of 2,863,070 shares. (Nasdaq: BIIB)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.